About Prostate Cancer


Prostate cancer is the 2nd most common cancer in men in the United States and is the second leading cause of death from cancer in men. The disease occurs more often in African-American men than in white men. African-American men are more likely to die from the disease than white men.

Prostate cancer can grow slowly and doesn’t usually produce symptoms in its earlier stages. Detecting prostate cancer is usually done by a Digital Rectal Exam (DRE), Prostate Specific Antigen Blood Test (PSA), UltraSound Imaging and TransRectal Biopsy.

Adenocarcinoma is the most common type. It is staged I thru IV depending on the type, amount and location. The staging process determines if the aggressiveness of the prostate cancer is considered Low, Intermediate or High. The stage will usually determine the options of treatments available to fight the disease.

The Gleason Score is determined by the Pathologist by looking at the patient’s biopsy tissue under a microscope. The more active the cancer cells, the higher the Gleason Score.

The PSA Score is determined by the lab by analyzing the patient’s blood. The more Prostate cancer fighting antigens in the blood, the higher the PSA Score.

Risk Groups:

  • Low – Gleason Score ≤ 6 & PSA < 10
  • Intermediate - Gleason Score = 7 & PSA = 10-20
  • High - Gleason Score ≥ 8 & PSA > 20

Choose Care Without Compromise!

Assign me a Personal Care Advocate

“HIFU allows me to target specific prostate tissue in a single outpatient treatment, minimizing side effects like ED.”

—Dr. Rashmi Patel